The regulatory status applies to AP-SA02, an intravenous treatment designed to manage complicated bacteremia caused by both methicillin-sensitive and methicillin-resistant Staphylococcus aureus. By securing this designation, Armata gains access to an expedited review process intended for therapies that demonstrate substantial clinical improvement over existing options for life-threatening conditions.

Management intends to coordinate closely with federal regulators to accelerate the development timeline for the candidate. Complicated S. aureus bloodstream infections currently represent a significant medical challenge, characterized by high rates of relapse and mortality. This development marks a pivot for the firm as it attempts to move the product candidate toward potential patient use.